![logo](/logos/ONCY.webp)
Oncolytics Biotech Inc.
NASDAQ:ONCY
0.96 (USD) • At close September 6, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Oncolytics Biotech Inc. |
Symbool | ONCY |
Munteenheid | USD |
Prijs | 0.958 |
Beurswaarde | 73,752,588 |
Dividendpercentage | 0% |
52-weken bereik | 0.85 - 2.35 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Matthew C. Coffey M.B.A., Ph.D. |
Website | https://www.oncolyticsbiotech.com |
An error occurred while fetching data.
Over Oncolytics Biotech Inc.
Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)